MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Cytokinetics Inc

Fermé

SecteurSoins de santé

40.29 7.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

37.5

Max

43.53

Chiffres clés

By Trading Economics

Revenu

11M

-150M

Ventes

16M

17M

BPA

-1.26

Marge bénéficiaire

-886.276

Employés

498

EBITDA

13M

-125M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+117.15% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-723M

5.1B

Ouverture précédente

32.85

Clôture précédente

40.29

Sentiment de l'Actualité

By Acuity

20%

80%

41 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Cytokinetics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2024, 15:26 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Comparaison

Variation de prix

Cytokinetics Inc prévision

Objectif de Prix

By TipRanks

117.15% hausse

Prévisions sur 12 Mois

Moyen 81.43 USD  117.15%

Haut 120 USD

Bas 62 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

16

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 42.705Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

41 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.